Tin tức & Cập nhật
Xem bài viết Dược
Xem
Ixa-dex, pom-dex both effective in heavily pretreated relapsed, refractory multiple myeloma
Ixazomib-dexamethasone (ixa-dex) and pomalidomide-dexamethasone (pom-dex) achieve comparable levels of efficacy and safety in relapsed and refractory multiple myeloma (RRMM) patients who had already been exposed to prior lenalidomide-based regimens, a recent study has found.
Antihypertensive drug does not lower death risk in HFrEF patients
Use of an antihypertensive drug does not appear to reduce the risk of all-cause mortality or hospital readmission in hospitalized older patients with heart failure with reduced ejection fraction (HFrEF) who are receiving contemporary treatments for HF, reveals a recent study.
Long-term steroid OK for RA but challenges guidelines
Contrary to what current guidelines advocate, long-term use of corticosteroid works fine in older patients with rheumatoid arthritis (RA), suggests the much-anticipated GLORIA* trial presented at EULAR 2022.
Microbiome-based therapy for recurrent CDI hits mark in patients with comorbidities
The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.
High-dose iberdomide shows promise in phase II SLE trial
In a phase II trial evaluating three doses of the high-affinity cereblon modulator iberdomide, the 0.45-mg dose demonstrated superiority over placebo for individuals with active, moderate-to-severe systemic lupus erythematosus (SLE).
